UNICHEM LABORATORIES LTD.

11th August 2026

Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Script Code: 506690

National Stock Exchange of India,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Symbol: UNICHEMLAB

Dear Sir/Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors at its Meeting held today, i.e. Tuesday, 11th August 2026 approved the Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026.

Enclosed herewith are the Unaudited Financial Statements (Consolidated & Standalone) for the first quarter ended 30th June 2026 alongwith Limited Review report by Auditors.

The Board meeting commenced at 12:00 noon and concluded at 1:45 p.m. The same will also be made available on the Company's website www.unichemlabs.com as well as on www.bseindia.com and www.nseindia.com.

Kindly take the same on your records.

Thanking you,

FOR UNICHEM LABORATORIES LIMITED

Pradeep Gautam Bhandari
Date: 2026.08.11 13:47:09 +05'30'

UNICHEM LABORATORIES LTD. MUMBAI 400 067

PRADEEP BHANDARI
Head – Legal & Company Secretary

Encl.: a/a

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June 2026

₹ Crores

	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	632.62	575.12	526.60	2,201.85
II	Other income	15.61	23.47	6.82	63.06
III	**Total income (I+II)**	**648.23**	**598.59**	**533.42**	**2,264.91**
IV	**EXPENSES**				
	Cost of materials consumed	190.02	184.03	217.48	768.83
	Purchase of stock-in-trade	67.25	91.81	51.01	231.51
	Changes in inventories of stock-in-trade, finished goods and work-in-progress	31.32	(7.82)	(23.44)	20.21
	Employee benefits expense (Refer note 6)	103.31	92.85	107.42	396.63
	Finance costs	6.62	9.39	6.54	31.59
	Depreciation and amortization expenses	29.94	30.61	31.79	125.12
	Other expenses	170.78	166.57	151.64	600.50
	Total expenses (IV)	**599.24**	**567.44**	**542.44**	**2,174.39**
V	Share of profit / (loss) in associate (net of tax)	-	-	-	-
VI	**Profit / (Loss) before exceptional items and tax (III- IV+V)**	**48.99**	**31.15**	**(9.02)**	**90.52**
VII	Exceptional items - expenses/(income) (Refer note 5)	-	12.36	-	(201.86)
VIII	**Profit / (Loss) before tax (VI-VII)**	**48.99**	**18.79**	**(9.02)**	**292.38**
IX	Tax expense (Refer note 4)				
	(1) Current tax	0.72	2.96	0.96	3.57
	(2) Deferred tax charge / (credit)	6.80	4.92	0.05	35.53
	(3) Short / (excess) provision for tax (earlier years)	-	-	0.44	0.44
		7.52	**7.88**	**1.45**	**39.54**
X	**Profit / (Loss) for the period after tax (VIII-IX)**	**41.47**	**10.91**	**(10.47)**	**252.84**
XI	Other Comprehensive Income / (Loss)				
	A. (i) Items that will not be reclassified subsequently to profit or loss				
	- Remeasurement of the net defined benefit plan	0.28	3.53	4.87	10.15
	(ii) Income tax (expense) / credit relating to items that will not be reclassified to profit or loss				
	- Remeasurement of the net defined benefit plan	(0.07)	(0.88)	-	(2.55)
	B. (i) Items that will be reclassified to profit or loss (Foreign currency translation difference)				
	-Foreign currency translation difference	(3.27)	6.51	(1.82)	4.39
	(ii) Income tax relating to items that will be reclassified to profit or loss				
	-Foreign currency translation difference	-	-	-	-
	Total of Other Comprehensive Income / (Loss)	**(3.06)**	**9.16**	**3.05**	**11.99**
XII	**Total Comprehensive Income/(loss) for the period (X+XI)**	**38.41**	**20.07**	**(7.42)**	**264.83**
XIII	Paid-up equity share capital (Face value of ₹ 2/- per share)	14.08	14.08	14.08	14.08
XIV	Other Equity (Reserves excluding revaluation reserve)				2,688.66
XV	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)				
	(1) Basic	5.89	1.55	(1.49)	35.91
	(2) Diluted	5.89	1.55	(1.49)	35.85

UNICHEM LABORATORIES LIMITED
Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Notes:

1 The above unaudited consolidated financial results ("the Statement") for the quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th August, 2026. The statutory auditors have expressed an unmodified conclusion on these consolidated financial results for the quarter ended 30th June, 2026.

2 The above Statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.

3 Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.

4 In respect of the Company, there is no current tax charge for the period, considering set-off of unabsorbed tax depreciation, capital loss and business loss. Further, deferred tax liability (net) has been recorded. In respect of subsidiaries, income tax is recognised as per applicable tax laws.

5 Exceptional Items comprise of the following:

₹ Crores

Particulars	**Quarter ended**			**Year ended**
	30.06.2026	**31.03.2026**	**30.06.2025**	**31.03.2026**
Employee benefit expense (refer note 6 below)	-	12.36	-	15.40
Net (gain) / loss on disposal of land & building [erstwhile Registered office]	-	-	-	(275.52)
Interest on European commission fine (refer note 7 below)	-	-	-	58.26
Total Exceptional Items – expenses / (income)	**-**	**12.36**	**-**	**(201.86)**

6 The New Labour Codes had resulted in a one-time increase in provision for employee benefits on account of recognition of past service costs of ₹ 15.40 crores which is disclosed as Exceptional Items during the year ended 31st March, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes.

7 The Company and its subsidiary Niche Generics Ltd. (“Niche”) had received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same was fully settled by the Company on 28th October 2025 after adjusting the payments of Euro 2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31st March 2024 and the balance amount representing the interest was recorded in year ended 31st March 2026 under exceptional items.

8 The figures for the quarter ended 31st March, 2026 are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the quarter ended 31st December, 2025 which were subjected to a limited review.

SIGNED FOR IDENTIFICATION
BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.08.11 13:27:18 +05'30'
N. A. SHAH ASSOCIATES LLP
MUMBAI

By Order of the Board
For Unichem Laboratories Limited
Pabitrakumar Kalipada Bhattacharyya
Date: 2026.08.11 13:00:18 +05'30'
Pabitrakumar Kalipada Bhattacharyya
Managing Director and Chief Executive Officer
DIN: 07131152

Place: Mumbai
Date: 11th August, 2026

UNICHEM

Independent Auditor's Review Report on Quarterly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Unichem Laboratories Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Unichem Laboratories Limited** ("the Holding Company"), comprising its subsidiaries (the Holding and its subsidiaries collectively referred to as "the Group") for the quarter ended 30th June 2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

Management's responsibility

2. The Statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's responsibility

3. Our responsibility is to issue a report on this Statement based on our review.

   We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Independent Auditor's Review Report on Quarterly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)

4. These consolidated unaudited financial results include results of the following subsidiaries:

   1) Niche Generics Limited, United Kingdom
   2) Unichem Pharmaceuticals (USA), Inc., USA
   3) Unichem SA (Pty) Limited, South Africa
   4) Unichem Farmaceutica Do Brasil Ltda, Brazil
   5) Unichem (China) Pvt. Ltd.

Basis for conclusion

5. Based on our review conducted and procedures performed as stated in above auditor's responsibility paragraph and based on the consideration of the review reports of the subsidiaries reviewed by another auditor and management certified accounts furnished to us, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

6. We did not review the interim financial statements of the subsidiary at USA and Niche, whose interim financial statements reflect total revenues (including other income) of Rs. 470.28 crores, total net profit / (loss) after tax and total comprehensive income of Rs. 12.39 crores for the quarter ended 30th June 2026 respectively as considered in the unaudited consolidated financial results. These financial results have been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the consolidated unaudited financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and our report in terms of the Listing Regulations (as amended), in so far as it relates to aforesaid subsidiaries located outside India is based on the report of other auditor and the procedures performed by us as stated in paragraph 3 above.

7. We also did not review the interim financial information of other subsidiaries as mentioned in paragraph 4 above, whose interim financial statements reflect total revenues (including other income) of Rs. 23.59 crores, total net profit / (loss) after tax and total comprehensive income of Rs. (0.08) crores for the quarter ended 30th June 2026 respectively as considered in the consolidated unaudited financial results. These financial information are not subject to limited review by their auditors and have been furnished to us by the Management and our conclusion on the consolidated unaudited financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is solely based on the information provided by the Management. According to the information and explanations given to us by the Management, these financial information are not material to the Group.

Independent Auditor's Review Report on Quarterly and year to date Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)

8. In case of associate, the carrying value of investment had been fully impaired. Further, financial information of associate is not available for the quarter ended 30th June 2026. In view of the above and in our opinion and according to the information and explanations given to us by the Management, this financial information is not material to the Group.

   Our conclusion on the Statement is not modified in respect of the matters stated in paragraph 6, 7 and 8 above.

For N. A. Shah Associates LLP
Chartered Accountants
Firm's Registration No.: 116560W / W100149

BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.08.11 13:17:11 +05'30'

Bhavin Kapadia
Partner
Membership No.: 118991
UDIN: 26118991GEDISE4454

Place: Mumbai
Date: 11th August, 2026

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June 2026

₹ Crores

	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	366.27	356.24	384.25	1,412.29
II	Other income	16.72	22.22	4.25	62.90
III	**Total income (I+II)**	**382.99**	**378.46**	**388.50**	**1,475.19**
IV	**EXPENSES**				
	Cost of materials consumed	168.80	149.98	203.88	671.59
	Purchase of stock-in-trade	0.17	0.23	0.12	1.05
	Changes in inventories of stock-in-trade, finished goods and work-in-progress	(14.53)	12.10	(22.08)	(7.28)
	Employee benefits expense (Refer note 5)	73.50	64.64	72.86	277.22
	Finance costs	1.29	4.09	1.93	11.80
	Depreciation and amortization expenses	28.69	28.97	29.93	119.03
	Other expenses	117.69	116.80	103.73	419.35
	Total expenses (IV)	**375.61**	**376.81**	**390.37**	**1,492.76**
V	**Profit / (Loss) before exceptional items and tax (III-IV)**	**7.38**	**1.65**	**(1.87)**	**(17.57)**
VI	Exceptional items - expenses/(income) (Refer note 4)	-	12.36	-	(226.98)
VII	**Profit / (Loss) before tax (V-VI)**	**7.38**	**(10.71)**	**(1.87)**	**209.41**
VIII	Tax expense (Refer note 7)				
	(1) Current tax	-	-	-	-
	(2) Deferred tax charge / (credit)	1.85	4.68	(0.46)	50.03
	(3) Short / (excess) provision for tax (earlier years)	-	-	0.44	0.44
		1.85	**4.68**	**(0.02)**	**50.47**
IX	**Profit / (Loss) for the period after tax (VII-VIII)**	**5.53**	**(15.39)**	**(1.85)**	**158.94**
X	Other Comprehensive Income / (Loss)				
	A. (i) Items that will not be reclassified subsequently to profit or loss				
	- Remeasurement of the net defined benefit plan	0.28	3.53	4.87	10.15
	(ii) Income tax (expense) / credit relating to items that will not be reclassified to profit or loss				
	- Remeasurement of the net defined benefit plan	(0.07)	(0.88)	(1.19)	(2.55)
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total of Other Comprehensive Income / (Loss)	**0.21**	**2.65**	**3.68**	**7.60**
XI	**Total Comprehensive Income/(loss) for the period (IX+X)**	**5.74**	**(12.74)**	**1.83**	**166.54**
XII	Paid-up equity share capital (Face value of ₹ 2/- per share)	14.08	14.08	14.08	14.08
XIII	Other Equity (Reserves excluding revaluation reserve)				2,598.32
XIV	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)				
	(1) Basic	0.79	(2.19)	(0.26)	22.57
	(2) Diluted	0.79	(2.19)	(0.26)	22.53

UNICHEM

Notes:

1. The above unaudited standalone financial results ("the Statement") for the quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th August, 2026. The statutory auditors have expressed an unmodified conclusion on these standalone financial results for the quarter ended 30th June, 2026.
2. The above Statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.
3. Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.
4. Exceptional Items comprise of the following:

₹ Crores

Particulars	Quarter ended			Year ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
Employee benefit expense (refer note 5 below)	-	12.36	-	15.40
Net (gain) / loss on disposal of land & building [erstwhile Registered office]	-	-	-	(275.52)
Interest on European commission fine (refer note 6 below)	-	-	-	58.26
Reversal of provision for European commission fine (net) (refer note 6 below)	-	-	-	(25.12)
Total Exceptional Items – expenses / (income)	**-**	**12.36**	**-**	**(226.98)**

5. The New Labour Codes had resulted in a one-time increase in provision for employee benefits on account of recognition of past service costs of ₹ 15.40 crores which is disclosed as Exceptional Items during the year ended 31st March, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes.
6. The Company and its subsidiary Niche Generics Ltd. ("Niche") had received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same was fully settled by the Company on 28th October 2025 after adjusting the payments of Euro 2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31st March 2024 and the balance amount representing the interest was recorded in year ended 31st March 2026 under exceptional items.
7. There is no current tax charge for the period, considering set-off of unabsorbed tax depreciation, capital loss and business loss. Further, deferred tax liability (net) has been recorded.
8. During the quarter ended 30th June 2026, the Company has invested USD 80,000 (equivalent to ₹ 0.76 crores) towards redeemable preference shares in its wholly owned subsidiary - "Unichem (China) Pvt Ltd."
9. The figures for the quarter ended 31st March, 2026 are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the quarter ended 31st December, 2025 which were subjected to a limited review.

SIGNED FOR IDENTIFICATION
BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.08.11 13:27:51 +05'30'
N. A. SHAH ASSOCIATES LLP
MUMBAI

By Order of the Board
For Unichem Laboratories Limited
Pabitrakumar Kalipada Bhattacharyya
Date: 2026.08.11 13:01:22 +05'30'
Pabitrakumar Kalipada Bhattacharyya
Managing Director and Chief Executive Officer
DIN: 07131152

Place: Mumbai
Date: 11th August, 2026

UNICHEM

N. A. SHAH ASSOCIATES LLP
Chartered Accountants

Independent Auditor's Review Report on Quarterly Standalone Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Unichem Laboratories Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of **Unichem Laboratories Limited** ("the Company") for the quarter ended 30th June 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

Management's responsibility

2. The Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's responsibility

3. Our responsibility is to issue a report on this Statement based on our review.

   We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

N. A. Shah Associates LLP is registered with limited liabililty having LLP identification No. AAG-7909
Regd. Off.: B 21-25, Paragon Centre, Pandurang Budhkar Marg, Worli, Mumbai 400 013.
Tel.: 91-22-40733000 • Fax : 91-22-40733090 • E-mail : info@nashah.com

Independent Auditor's Review Report on Quarterly Standalone Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of standalone unaudited financial results, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards i.e. 'Ind AS' prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. A. Shah Associates LLP
Chartered Accountants
Firm's Registration No.: 116560W / W100149

BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.08.11 13:16:05 +05'30'

Bhavin Kapadia
Partner
Membership No.: 118991
UDIN: 26118991XBLNQD5675

Place: Mumbai
Date: 11th August, 2026